Therapeutic approaches to innate immunity: Severe sepsis and septic shock

被引:61
作者
Lolis, E
Bucala, R
机构
[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Med & Pathol, New Haven, CT 06520 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nrd1153
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Severe sepsis leading to shock is the principal cause of death in non-cardiac intensive care units. This condition develops because of a dysregulation in host responses, such that the mechanisms initially recruited to fight infection produce life-threatening tissue damage and death. Recent advances in our understanding of innate immunity, and the interaction between the inflammatory and the haemostatic cascades, are affording new opportunities for therapeutic development. This article discusses selected pathophysiological mechanisms that might yield to therapeutic intervention, considers rationales for the resurrection of previously failed drugs, and highlights new targets that have shown promise in preclinical studies.
引用
收藏
页码:635 / 645
页数:11
相关论文
共 105 条
[11]  
Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635
[12]   A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis [J].
Baugh, JA ;
Chitnis, S ;
Donnelly, SC ;
Monteiro, J ;
Lin, X ;
Plant, BJ ;
Wolfe, F ;
Gregersen, PK ;
Bucala, R .
GENES AND IMMUNITY, 2002, 3 (03) :170-176
[13]  
BAUMGARTNER JD, 1985, LANCET, V2, P59
[14]   Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness [J].
Beishuizen, A ;
Thijs, LG ;
Haanen, C ;
Vermes, I .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06) :2811-2816
[15]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[16]   MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA [J].
BERNHAGEN, J ;
CALANDRA, T ;
MITCHELL, RA ;
MARTIN, SB ;
TRACEY, KJ ;
VOELTER, W ;
MANOGUE, KR ;
CERAMI, A ;
BUCALA, R .
NATURE, 1993, 365 (6448) :756-759
[17]   RECOMBINANT TUMOR-NECROSIS-FACTOR INDUCES PROCOAGULANT ACTIVITY IN CULTURED HUMAN VASCULAR ENDOTHELIUM - CHARACTERIZATION AND COMPARISON WITH THE ACTIONS OF INTERLEUKIN-1 [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
FIERS, W ;
COTRAN, RS ;
GIMBRONE, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4533-4537
[18]   Cutting edge: A toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling [J].
Bochud, PY ;
Hawn, TR ;
Aderem, A .
JOURNAL OF IMMUNOLOGY, 2003, 170 (07) :3451-3454
[19]   A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J].
BONE, RC ;
BALK, RA ;
FEIN, AM ;
PERL, TM ;
WENZEL, RP ;
REINES, HD ;
QUENZER, RW ;
IBERTI, TJ ;
MACINTYRE, N ;
SCHEIN, RMH ;
TRENHOLME, G ;
NIEDERMAN, M ;
CHALFIN, D ;
ABALOS, A ;
OROPELLO, J ;
EMPSON, P ;
CAMINITII, S ;
GREENMAN, R ;
BOOTH, F ;
PLOUFFE, J ;
RUSSELL, J ;
GIANAKOPOULOS, G ;
IANNINI, P ;
HINDES, R ;
COBLENS, K ;
KOHLER, R ;
MARTIN, M ;
BERNARD, G ;
EDWARDS, J ;
CRISLIP, M ;
FILLER, S ;
NASRAWAY, SA ;
SIGEL, PK ;
SOTTILE, FD ;
MARTIN, DH ;
DEBOISBLANC, BP ;
CHANDRASEKAR, PH ;
BROUGHTON, WA ;
MIDDLETON, RM ;
SEIBERT, AF ;
EMMANUEL, G ;
LIE, TH ;
ANDERSON, CLV ;
PANKEY, GA ;
ANDERSON, P ;
OLSEN, K ;
SANPEDRO, GS ;
GRAHAM, D ;
GROSSMAN, J ;
WELS, PB .
CRITICAL CARE MEDICINE, 1995, 23 (06) :994-1006
[20]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655